<DOC>
	<DOCNO>NCT02145039</DOCNO>
	<brief_summary>This treatment guideline HLA-Haploidentical hematopoietic stem cell transplant ( HSCT ) use reduce intensity conditioning ( RIC ) regimen . This regimen , consist fludarabine , cyclophosphamide low dose total body irradiation ( TBI ) , design treatment patient advance and/or high risk disease .</brief_summary>
	<brief_title>Reduced Intensity Conditioning Haploidentical Related Bone Marrow Patients With Hematologic Diseases</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Must &lt; 75 year old 7/8 8/8 HLAmatched sibling donor One potential relate mismatched donor ( e.g . biologic parent ( ) sibling ( full half ) child ) . Low resolution use DNA base type HLAA , B DRB1 potential haploidentical donor require . All disease list advanced hematologic malignancy curable conventional chemotherapy . Responses conventional treatment range zero 30 % typically short live . Acute Lymphoblastic Leukemia ( ALL ) first complete remission ( CR1 ) NOT consider favorablerisk . Acute Myelogenous Leukemia ( AML ) first complete remission ( CR1 ) NOT consider favorablerisk . Acute Leukemias 2nd subsequent CR Biphenotypic/Undifferentiated/Prolymphocytic Leukemias first subsequent CR , adult Tcell leukemia/lymphoma first subsequent CR Burkitt 's lymphoma CR2 subsequent CR Natural killer cell malignancy response initial therapy Chronic myelogenous leukemia : type except refractory blast crisis . Largecell lymphoma , Hodgkin lymphoma multiple myeloma chemotherapy sensitive disease fail patient ineligible autologous transplant . Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma , follicular lymphoma , progress within 12 month achieve partial complete remission . Lymphoplasmacytic lymphoma , mantlecell lymphoma , prolymphocytic leukemia eligible initial therapy chemotherapy sensitive . Refractory leukemia MDS These patient may take transplant aplasia induction reinduction chemotherapy radiolabeled antibody . Bone marrow failure syndrome , except Fanconi Anemia Myeloproliferative syndrome Adequate organ function define : Cardiac : Absence decompensated congestive heart failure , uncontrolled arrhythmia leave ventricular ejection fraction &gt; 35 % . For child able cooperate MUGA echocardiography , clearly state physician 's note Pulmonary : DLCO &gt; 30 % predict , absence O2 requirement . For child able cooperate PFTs , pulse oximetry exercise attempt . If nether test obtain clearly state physician 's note . Liver : Transaminases &lt; 5 x upper limit normal bilirubin &lt; 3 x upper limit normal Renal : serum creatinine &lt; 2.0 mg/dl ( adult ) glomerular filtration rate ( GFR ) &gt; 40 mL/min/1.73m2 ( peds ) . Patients creatinine &gt; 1.2 mg/dl history renal dysfunction must glomerular filtration rate ( GFR ) &gt; 40 mL/min/1.73m2 . Adequate performance status define Karnofsky score ≥ 60 % ( &gt; 16 year age ) Lansky score ≥ 50 ( pediatrics ) If recent mold infection e.g . Aspergillus must minimum 30 day appropriate treatment BMT infection control clear Infectious Disease . Second BMT : Must &gt; 3 month prior myeloablative transplant . Patients must ineligible autologous transplantation due prior autologous transplant , inadequate autologous stem cell harvest , inability withstand myeloablative preparative regimen , clinically aggressive/high risk disease . Patients eligible transplantation evidence progressive disease image modality biopsy . Persistent PET activity , though possibly relate lymphoma , exclusion criterion absence CT change indicate progression . Patients stable disease eligible transplantation large residual nodal mass &lt; 5 cm ( approximately ) . For patient respond precede therapy , large residual mass must represent 50 % reduction &lt; 7.5 cm ( approximately ) . Voluntary write consent ( adult parental/guardian ) Available clinically suitable 56/6 HLAA , B , DRB1 match sibling donor Pregnant breastfeeding Evidence HIV infection know HIV positive serology Current active serious infection Unless postchemotherapy radioimmunoconjugated antibody induced aplasia , he/she would eligible , patient acute leukemia morphologic relapse/ persistent disease define &gt; 5 % blast normocellular bone marrow OR % blast blast unique morphologic marker ( e.g . Auer rod ) associate cytogenetic marker allow morphologic relapse distinguish eligible . CML refractory blast crisis Large cell lymphoma , mantle cell lymphoma Hodgkin disease progressive salvage therapy . Stable disease acceptable move forward provide nonbulky . active central nervous system malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia ( ALL )</keyword>
	<keyword>Acute Myelogenous Leukemia ( AML )</keyword>
	<keyword>Burkitt 's lymphoma</keyword>
	<keyword>Natural killer cell malignancy</keyword>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Large-cell lymphoma</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Chronic lymphocytic leukemia ( CLL )</keyword>
	<keyword>Small lymphocytic lymphoma ( SLL )</keyword>
	<keyword>Marginal zone B-cell lymphoma</keyword>
	<keyword>Follicular lymphoma</keyword>
	<keyword>Lymphoplasmacytic lymphoma</keyword>
	<keyword>Mantle-cell lymphoma</keyword>
	<keyword>Prolymphocytic leukemia</keyword>
	<keyword>Refractory leukemia</keyword>
	<keyword>MDS</keyword>
	<keyword>Bone marrow failure syndrome</keyword>
	<keyword>Myeloproliferative syndrome</keyword>
</DOC>